Skip to contentpdufa.bio

AMT-260 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

AMT-260 Phase is an uniQure N.V. program in refractory mesial temporal lobe epilepsy (MTLE). Its next catalyst is a Readout in Q2 2027.

QURE catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Refractory mesial temporal lobe epilepsy (MTLE). Sponsor: uniQure N.V. (QURE). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027QURE

Specialist biotech funds holding QURE, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Avoro Capital Advisors6,727,777$162.5 millionfiled November 16, 2026
RTW Investments3,941,572$95.2 millionfiled November 16, 2026
OrbiMed Advisors811,000$19.6 millionfiled November 16, 2026
Perceptive Advisors402,773$9.7 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is AMT-260 Phase's next FDA decision or readout?

The next tracked catalyst for AMT-260 Phase is a Readout in Q2 2027.

What happened at AMT-260 Phase's most recent FDA decision?

No FDA decision for AMT-260 Phase is in our archive yet.

What is AMT-260 Phase used for?

In our records AMT-260 Phase is under review or in development for Refractory mesial temporal lobe epilepsy (MTLE).

Who makes AMT-260 Phase?

uniQure N.V. (QURE).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.